{"url_path":"/sec/wgrx/8-k/2026-05-21/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2030763/0001493152-26-024723-index.html","accession_number":"0001493152-26-024723","cik":"0002030763","ticker":"WGRX","issuer_name":"Wellgistics Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2030763/0001493152-26-024723-index.html","primary_entity_key":"0002030763","primary_entity_name":"Wellgistics Health, Inc."},"word_count":434,"has_tables":true,"body_markdown":"**Item\n5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n** **\n\nOn\nMay 20, 2026, in connection with the Term Sheet described in Item 1.01 of this Current Report on Form 8-K, the Board of Directors\nof Wellgistics Health, Inc. (the “Company”) appointed Gerald Commissiong as Interim Co-Chief Executive Officer of the Company,\neffective immediately. Mr. Commissiong will serve alongside the Company’s current President and Interim Co-Chief Executive Officer.\n\n \n\nMr.\nCommissiong has served as our Chief Business Officer since February 2026 and currently serves as Managing Partner of Fortitude Advisors, LLC and\nas Chief Executive Officer of Tollo Health, LLC, d/b/a Health Lives Here. Mr. Commissiong has extensive experience in healthcare, biotechnology,\nlife sciences and strategic advisory services, including leadership positions involving public and private companies, business development,\nstrategic partnerships and capital markets transactions. For more than 15 years, Mr. Commissiong has been a senior executive officer\nof publicly held, emerging growth healthcare companies. He served as the Chief Executive Officer and director of Todos Medical Ltd.,\nan in vitro diagnostics company focused on the development of novel blood tests for the early detection\n\n \n\nMr.\nCommissiong’s appointment as Interim Co-Chief Executive Officer was made pursuant to the Binding Letter of Intent and is expected\nto be memorialized through an addendum to Fortitude Advisors LLC’s existing consulting agreement with the Company relating to consulting\nChief Business Officer services. The material terms of any such addendum have not yet been finalized as of the date of this Current Report\non Form 8-K.\n\n \n\nFortitude\nAdvisors, LLC is a party to the Term Sheet described in Item 1.01 of this Current Report on Form 8-K and, pursuant to the contemplated transaction\ndescribed therein, Fortitude Advisors, LLC is expected to receive Acquisition Preferred that would be convertible, subject to the terms\nand conditions of the definitive agreements, into shares representing approximately 5.0% of the Company’s common stock following\nconversion of such preferred stock. Mr. Commissiong’s relationship with Fortitude Advisors, LLC and HealthBridge Advisors, LLC,\nand their participation in the proposed transaction, constitute arrangements or understandings pursuant to which Mr. Commissiong was\nappointed as Interim Co-Chief Executive Officer of the Company.\n\n \n\nThere\nare no family relationships between Mr. Commissiong and any director or executive officer of the Company. Except as described above and\nin Item 1.01 of this Current Report on Form 8-K, there are no transactions involving Mr. Commissiong requiring disclosure under Item\n404(a) of Regulation S-K.\n\n \n\nThe\ndisclosure contained in Item 1.01 of this Current Report on Form 8-K relating to the Term Sheet is incorporated herein by reference."}